| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |